Original Research
Published on 29 Sep 2022
Intermittent MEK inhibition for the treatment of metastatic uveal melanoma
in Skin Cancer
Frontiers in Oncology
doi 10.3389/fonc.2022.975643
- 6,182 views
- 8 citations
15 articles related to "Mek Inhibition"
Articles
Original Research
Published on 21 Feb 2023
MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
in Pediatric Oncology
Frontiers in Oncology
doi 10.3389/fonc.2023.1130034
- 4,470 views
- 9 citations
Case Report
Published on 12 Jul 2024
Case report: Treatment response of NF-1-associated bladder ganglioneuroma to trametinib
in Pediatric Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1433073
- 2,108 views
- 1 citation
Mini Review
Published on 20 Dec 2024
The role of MEK inhibition in pediatric low-grade gliomas
in Pediatric Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1503894
- 4,291 views
- 3 citations
Review
Published on 27 Jul 2022
Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.931774
- 13,623 views
- 41 citations
Original Research
Published on 09 Jun 2023
A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma
in Skin Cancer
Frontiers in Oncology
doi 10.3389/fonc.2022.975642
- 6,716 views
- 10 citations
Original Research
Published on 18 Jan 2017
The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia
in Clinical and Translational Physiology
Frontiers in Physiology
doi 10.3389/fphys.2016.00682
- 7,189 views
- 29 citations
Systematic Review
Published on 14 Jun 2021
Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis
in Skin Cancer
Frontiers in Oncology
doi 10.3389/fonc.2021.693655
- 8,696 views
- 29 citations
Case Report
Published on 27 Sep 2022
Case Report: Progressive central conducting lymphatic abnormalities in the RASopathies. Two case reports, including successful treatment by MEK inhibition
in Human and Medical Genomics
Frontiers in Genetics
doi 10.3389/fgene.2022.1001105
- 6,501 views
- 24 citations
Review
Published on 25 Mar 2021
Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives
in Gastrointestinal Cancers
Frontiers in Oncology
doi 10.3389/fonc.2021.602194
- 12,010 views
- 12 citations
Case Report
Published on 01 Mar 2021
Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma
in Skin Cancer
Frontiers in Oncology
doi 10.3389/fonc.2021.643156
- 7,176 views
- 12 citations
Review
Accepted on 06 Mar 2026
Vascular Malformations of the Head and Neck and a Molecularly Guided Precision Therapy Framework
in Endovascular and Interventional Neurology
Frontiers in Neurology
Original Research
Published on 24 Nov 2025
Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1663502
- 2,040 views
Original Research
Published on 05 Feb 2026
BRAF and MEK inhibition beyond dabrafenib–trametinib in advanced thyroid cancer: a real-world case series
in Thyroid Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2026.1694805
- 621 views
Original Research
Published on 15 Jun 2022
Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.893635
- 6,892 views
- 11 citations